acute 060727 transfusionmed

Information about acute 060727 transfusionmed

Published on October 23, 2007

Author: Alien

Source: authorstream.com

Content

Transfusion Medicine and Hemolytic Anemias:  Transfusion Medicine and Hemolytic Anemias John Densmore, MD, PhD Division of Hematology/Oncology July 2005 Overview:  Overview Transfusion Medicine Indications Products Complications Autoimmune Hemolysis Evaluation Treatment Transfusion Medicine:  Transfusion Medicine Indications: Red cells: symptomatic anemia (Young people may tolerate Hct <20, elderly/CAD may be symptomatic <30) Platelets: Prophylactic: <10,000 (<20 if febrile). <50 for procedures, <80-100 for major surgery FFP: for coagulopathy, massive blood transfusion, factor deficiency. Cryoprecipitate: for low fibrinogen (DIC) or third line for von Willebrand’s disease Packed Red Blood Cells:  Packed Red Blood Cells Reduced plasma volume, hct 70-80% Volume 260 ml Matched for ABO type 1 unit should increase hgb by 1 g/dL Platelets:  Platelets Random donor 50-70ml per unit Stored at room temp 6 units should increase plt by 30,000 Single donor 200-400 ml Equivalent to pool of 6 units random donor No significant benefit over random donor, unless matched Fresh Frozen Plasma:  Fresh Frozen Plasma Contains all coagulation factors Volume 200-260 ml per unit Dose of 10-20ml/kg (4-6 units for adult) will increase coag factors by 20% T1/2 of FVII is 6 hours Cryoprecipitate:  Cryoprecipitate Contains FVIII, vWF, fibrinogen, FXIII Treatment of choice for low fibrinogen Given in 10 bag increments Will raise fibrinogen by 40-50 mg/dL Activated FVII:  Activated FVII Indicated for pts with hemophilia and factor inhibitors Used for temporary correction of coagulopathy (ie, procedure) Major contraindication: MI, angina, CVA within several weeks Activated FVII:  Activated FVII Protocol: 40mcg/kg within 1 hr of procedure, followed by 20-40mcg/kg 2 hrs after (may repeat q4hr x 1 or 2 doses) Fibrinogen should be >150 mg/dL Complications:  Complications Prevention Transfusion reactions Infectious Other Leukodepletion:  Leukodepletion Prevention of febrile transfusion reactions in a patient with previous documented reactions Prevention of HLA alloimmunization (ineffective if patient has receive one or more blood products not leukodepleted or already HLA immunized) Prevention of CMV infection Irradiation:  Irradiation Performed to prevent transfusion-associated graft-versus-host-disease (TA-GVHD) Absolute Indications: BMT recipients, congenital immune deficiencies, transfusion from relatives, Hodgkin Lymphoma (current or history of). Probable: Hematologic malignancies other than HL, those receiving aggressive chemotherapy, HLA-matched platelets. Not Indicated: HIV/AIDS, elderly, hemophilia, solid tumor patients, those on immunosuppressants Transfusion Reaction:  Transfusion Reaction Defined as a rise in temperature of 1oC during transfusion May have associated signs/symptoms of chills, rigors, headache, nausea, tachycardia, dyspnea, hypotension Can occur during transfusion or up to 24hr after Most are not life threatening, but each needs to be worked up to rule out acute hemolysis Most common is a febrile, non-hemolytic reaction due to either WBC or cytokines in transfused unit Acute Hemolytic Transfusion Reaction:  Acute Hemolytic Transfusion Reaction Most common cause is ABO mismatch Usually massive intravascular hemolysis with hemoglobinemia and hemoglobinuria (risk of ARF) Workup: CBC, repeat T+S, DAT, U/A Treatment: stop transfusion, vigorous hydration, maintenance of BP Mortality related to amount of blood transfused, organ failure Delayed Hemolytic Transfusion Reaction:  Delayed Hemolytic Transfusion Reaction Occurs several days to a week after transfusion Recipient antibodies to transfused unit that were not detected on T+S (but previous exposure to the antigen) Causes lack of expected rise in Hct, fever, Coomb’s positive hemolytic anemia, jaundice. Repeat T+S will demonstrate antibody to an antigen on the transfused unit. Most often directed against Rh, Kidd, Duffy, Kell, E, Jk. Infections: Screening:  Infections: Screening Hepatitis B surface antigen (HBsAg) Hepatitis B core antibody (anti-HBc) Hepatitis C virus antibody (anti-HCV) HIV-1 and HIV-2 antibody (anti-HIV-1 and anti-HIV-2) HTLV-I and HTLV-II antibody (anti-HTLV-I and anti-HTLV-II) Serologic test for syphilis Nucleic acid amplification testing (NAT) for HIV-1 and HCV NAT for West Nile Virus Infectious Complications:  Infectious Complications Bacterial: can occur with any transfusion, more likely after platelets because they are stored at room temperature. Platelets: Staph. Epi. And Bacillus Cereus most common; estimated to occur in 1:2000 units with risk of severe sepsis in 1:50,000 RBC: Yersinia, Serratia and Pseudomonas most common; risk of severe sepsis in 1: 500,000 units Infectious Complications:  Infectious Complications Viral: HIV: current estimates are that fewer than 1 in 2,100,000 blood components is capable of transmitting HIV with nucleic acid testing . Hepatitis B: In 2000, the frequency of post-transfusion hepatitis B was estimated at 1 in 205,000 screened units of blood. Hepatitis C: the risk of HCV transmission through transfusion is less than 1 per 1,900,000-screened units of blood. Other Infections: HTLV-I, CMV, West nile virus, malaria, syphilis, Chagas disease and babesiosis have been linked to transfusions Transfusion Related Acute Lung Injury (TRALI) :  Transfusion Related Acute Lung Injury (TRALI) Hypoxemia, fever, bilateral infiltrates and hypotension developing 2-4 hours after transfusion Major differential includes CHF/volume overload, infection Estimated risk is 1:5,000 to 1:1,323 per component transfused Third most common cause of transfusion-related death. TRALI:  TRALI Chest. 2004;126:249-258 TRALI:  TRALI A form of ARDS caused by the presence of HLA antibodies in the donor serum leading to destruction of host granulocytes and activation of the complement system leading to lung injury Treatment is supportive. Ventilatory support may be required Recovery is usually rapid and complete Transfusion Related Graft vs. Host Disease (TGVH) :  Transfusion Related Graft vs. Host Disease (TGVH) Occurs when donor lymphocytes attack the recipient Very rare in the normal blood recipient unless the donor is homozygous for an HLA haplotype and recipient is heterozygous for that haplotype (related donor) TGVH is reported in blood recipients who are immunosuppressed- mainly patients with Hodgkin's disease and leukemia TGVHD:  TGVHD Symptoms are an erythematous rash that may progress to toxic epidermal necrolysis, liver dysfunction and pancytopenia TGVH is prevented by irradiating blood products for at risk patients with 1500-3500 rads Platelet Alloimmunization :  Platelet Alloimmunization Patients exposed to WBC with different HLA types will develop antibodies to HLA antigens Platelets express class I HLA antigens and are rapidly destroyed by HLA antibodies. Seen in patients who have received previous transfusions of blood that is not leukodepleted or patients who have been pregnant Platelet Alloimmunization:  Platelet Alloimmunization Up to 90% of patients with aplastic anemia or myelodysplasia will become HLA immunized. Incidence is less in patients receiving chemotherapy but still can be as high as 60 - 90%. Important to leukodeplete all products for pts who will receive frequent transfusions (BMT, acute leukemia, MDS, AA) Use of Anti-D with platelet transfusions:  Use of Anti-D with platelet transfusions Platelets do not express Rh antigens, but contaminating RBC do Rh- patients will occasionally receive platelets from Rh+ donor 0.1 ml of RBC enough to elicit anti-D response Use of Anti-D with platelet transfusions:  Use of Anti-D with platelet transfusions Blood bank will recommend RhoGam for Rh- pt that receives Rh+ plt Data to support its use in premenopausal females who may become pregnant No benefit in men or post-menopausal women Dose is 250 iu given SC (will cover for 6 weeks) Anaphylaxis :  Anaphylaxis Suspect in patient with bronchospasm, wheezing or other sign of anaphylaxis within an hour of transfusion Most common cause is an IgA-deficient patient that has anti-IgA antibodies and reacts to the plasma Treatment is supportive with avoidance of plasma if possible Red Cell Disorders:  Red Cell Disorders Anemia Underproduction Hemolytic Enzyme defects Hemoglobinopathies Approach to anemia:  Approach to anemia Hemolytic Anemia:  Hemolytic Anemia Autoimmune Hemolytic Anemia Warm Cold Drug-related G6PD Inherited enzyme defects Approach to Anemia with High Reticulocyte Count:  Approach to Anemia with High Reticulocyte Count Smear (spherocytes, fragments) Bilirubin, LDH, Haptoglobin Direct and Indirect Coombs Urinalysis Direct Antiglobulin Test:  Direct Antiglobulin Test Indirect Antiglobulin Test:  Indirect Antiglobulin Test Uses panel of RBC with known antigen expression; can define the antigen that is targeted Direct Antiglobulin Test (Coomb’s):  Direct Antiglobulin Test (Coomb’s) Warm AIHA:  Warm AIHA Associated with lymphoproliferative d/o, autoimmune disease (most idiopathic) Incr. retic, Coombs pos, haptoglobin low, spherocytes Treatment: steroids, IVIG Transfusions are OK if needed Splenectomy for refractory pts Normal smear:  Normal smear Spherocytes:  Spherocytes Cold AIHA:  Cold AIHA IgM: associated with lymphoproliferative d/o, mononucleosis, mycoplasma IgG: classic is syphilis (Donath-Landsteiner Ab), also drug-related Warm blood, keep pt warm, steroids Drug-Induced HA:  Drug-Induced HA 3 types: Autoantibody (methyldopa, procainamide) Coomb’s positive for IgG and C3 Hapten-mediated (penicillins) Coomb’s pos for IgG, not C3 Innocent bystander (Immune complex) Coomb’s pos for C3 Quinidine, HCTZ, NSAIDs, Sulfonylureas Slide41:  Hapten (penicillin) Autoantibody (methyldopa) Treatment:  Treatment Stop any offending drugs Steroids Transfusions

Related presentations


Other presentations created by Alien

Physical Security Lecture
05. 01. 2008
0 views

Physical Security Lecture

GREEK THEATRE
15. 10. 2007
0 views

GREEK THEATRE

Singapore National Symbols
14. 09. 2007
0 views

Singapore National Symbols

Origins of the Cold War
23. 12. 2007
0 views

Origins of the Cold War

CG43SlideSet
30. 04. 2008
0 views

CG43SlideSet

kaiser pres
28. 04. 2008
0 views

kaiser pres

GoldDifferences
22. 04. 2008
0 views

GoldDifferences

visn8
17. 04. 2008
0 views

visn8

Nov24 Regulatory approaches
16. 04. 2008
0 views

Nov24 Regulatory approaches

dr rom
14. 04. 2008
0 views

dr rom

file 6943
13. 04. 2008
0 views

file 6943

The Peak Oil Context Tom Petrie
10. 04. 2008
0 views

The Peak Oil Context Tom Petrie

H106g
09. 04. 2008
0 views

H106g

JapaneseGeography
07. 04. 2008
0 views

JapaneseGeography

Hamburg 2007
14. 09. 2007
0 views

Hamburg 2007

lfg
14. 09. 2007
0 views

lfg

Eddie Final Presentation
14. 09. 2007
0 views

Eddie Final Presentation

chalmers
14. 09. 2007
0 views

chalmers

The Rain Forest Final
14. 09. 2007
0 views

The Rain Forest Final

ECAKnowledgeFair
12. 10. 2007
0 views

ECAKnowledgeFair

Ch18part1
15. 10. 2007
0 views

Ch18part1

WNV AVB 02212006
21. 10. 2007
0 views

WNV AVB 02212006

giraffe pp
14. 09. 2007
0 views

giraffe pp

giraffe powerpoint
14. 09. 2007
0 views

giraffe powerpoint

giraffe
14. 09. 2007
0 views

giraffe

COOL STUFF ABOUT GIRAFFES
14. 09. 2007
0 views

COOL STUFF ABOUT GIRAFFES

ub041104
23. 10. 2007
0 views

ub041104

STORY OF THEME AND PLOT
23. 10. 2007
0 views

STORY OF THEME AND PLOT

PhiladelphiaZooPPP
14. 09. 2007
0 views

PhiladelphiaZooPPP

qu10 11
01. 12. 2007
0 views

qu10 11

Angelos CME Energetics
02. 11. 2007
0 views

Angelos CME Energetics

pptPanama s
22. 10. 2007
0 views

pptPanama s

hirotani
13. 11. 2007
0 views

hirotani

bon2003 mpls
29. 10. 2007
0 views

bon2003 mpls

PROF AZZA
23. 10. 2007
0 views

PROF AZZA

Fenton
29. 10. 2007
0 views

Fenton

Countering Offshore
29. 12. 2007
0 views

Countering Offshore

walters082902
23. 11. 2007
0 views

walters082902

razbash
26. 11. 2007
0 views

razbash

DVMRPandMOSPF
01. 01. 2008
0 views

DVMRPandMOSPF

One 783Ngupta
04. 01. 2008
0 views

One 783Ngupta

Chapter 18 PPT
22. 10. 2007
0 views

Chapter 18 PPT

History of NAIS John Wiemers
20. 08. 2007
0 views

History of NAIS John Wiemers

BSP2D
14. 09. 2007
0 views

BSP2D

costarica1 ftparraud
22. 10. 2007
0 views

costarica1 ftparraud

mcmc2000a
06. 11. 2007
0 views

mcmc2000a

050317lc
16. 11. 2007
0 views

050317lc

ALA2003 OAI
04. 10. 2007
0 views

ALA2003 OAI

fwing
22. 10. 2007
0 views

fwing

bckexpk3b
09. 07. 2007
0 views

bckexpk3b

anorexia
09. 07. 2007
0 views

anorexia

070207 Adjektiv
09. 07. 2007
0 views

070207 Adjektiv

A Brachmann
09. 10. 2007
0 views

A Brachmann

mueller jun07
19. 10. 2007
0 views

mueller jun07

Late Classic Maya Collapse
16. 02. 2008
0 views

Late Classic Maya Collapse

ISLAS GALAPAGOS
14. 09. 2007
0 views

ISLAS GALAPAGOS

Heatingoilwebsection ppp
24. 02. 2008
0 views

Heatingoilwebsection ppp

PIndustrialTrucks
26. 02. 2008
0 views

PIndustrialTrucks

ethanap
14. 09. 2007
0 views

ethanap

Propulsion CEV
07. 11. 2007
0 views

Propulsion CEV

MichelleWatt
20. 02. 2008
0 views

MichelleWatt

newsletterfall04
11. 03. 2008
0 views

newsletterfall04

EC T9 2008 Conference Proposal
12. 03. 2008
0 views

EC T9 2008 Conference Proposal

drugstatistics
17. 12. 2007
0 views

drugstatistics

icfa chep06
23. 10. 2007
0 views

icfa chep06

Hubert CW8
14. 09. 2007
0 views

Hubert CW8

A mi Papi 2089
19. 06. 2007
0 views

A mi Papi 2089

An ode to Mothers
19. 06. 2007
0 views

An ode to Mothers

LoffPresentation
17. 10. 2007
0 views

LoffPresentation

Maschera
19. 06. 2007
0 views

Maschera

manual
19. 06. 2007
0 views

manual

Luces De Navidad 1848
19. 06. 2007
0 views

Luces De Navidad 1848

leer
19. 06. 2007
0 views

leer

Lean Six SigmaATL011706
19. 06. 2007
0 views

Lean Six SigmaATL011706

lexisnexis
05. 10. 2007
0 views

lexisnexis

OAT Presentation v5
19. 06. 2007
0 views

OAT Presentation v5

moscatelli
19. 06. 2007
0 views

moscatelli

moon split
19. 06. 2007
0 views

moon split

money plus
19. 06. 2007
0 views

money plus

MKCL
19. 06. 2007
0 views

MKCL

Journey of the Spirit Lesson 6
01. 10. 2007
0 views

Journey of the Spirit Lesson 6

2 Jornada BISHOP
10. 10. 2007
0 views

2 Jornada BISHOP

No esperes
19. 06. 2007
0 views

No esperes

Amores locos 1992
19. 06. 2007
0 views

Amores locos 1992

College English book 2 Unit 7
24. 02. 2008
0 views

College English book 2 Unit 7

A vista de pajaro II 2109
19. 06. 2007
0 views

A vista de pajaro II 2109

Ammosov Vladimir ammosov pra
12. 10. 2007
0 views

Ammosov Vladimir ammosov pra

Amber la mejor de todas
19. 06. 2007
0 views

Amber la mejor de todas

CP317 lecture 6 Huck II 05
11. 12. 2007
0 views

CP317 lecture 6 Huck II 05

AHQA031204Mck
09. 07. 2007
0 views

AHQA031204Mck

Evergreen
03. 01. 2008
0 views

Evergreen

04 NJIT3
02. 01. 2008
0 views

04 NJIT3

Poster A4 Glasgow nov04
04. 10. 2007
0 views

Poster A4 Glasgow nov04

Ally McBeal
09. 07. 2007
0 views

Ally McBeal

sara paige
14. 09. 2007
0 views

sara paige

36181003
24. 10. 2007
0 views

36181003

MusicApprecBaroque 2
22. 11. 2007
0 views

MusicApprecBaroque 2

ELE386 Malware
20. 08. 2007
0 views

ELE386 Malware

RohanShah
12. 10. 2007
0 views

RohanShah

1022MAS net big picture
03. 01. 2008
0 views

1022MAS net big picture

Lo Suficiente 1744
19. 06. 2007
0 views

Lo Suficiente 1744

gm3 jp item14 Mangrove ITTO
22. 10. 2007
0 views

gm3 jp item14 Mangrove ITTO

2005AuditResults
09. 07. 2007
0 views

2005AuditResults

HABIC1 summary
17. 11. 2007
0 views

HABIC1 summary

aro ald informalsession
24. 10. 2007
0 views

aro ald informalsession

etu ambassadeurs juin 07 en
13. 03. 2008
0 views

etu ambassadeurs juin 07 en

Gobert poster
03. 10. 2007
0 views

Gobert poster

Kistenev
15. 11. 2007
0 views

Kistenev

6 History of Chemistry I
12. 10. 2007
0 views

6 History of Chemistry I

Jan2000report
04. 01. 2008
0 views

Jan2000report

course 4
03. 01. 2008
0 views

course 4